Synthetic Lethality Summit 2018

Synthetic Lethality Summit is organized by Hanson Wade and will be held during Jan 30 - Feb 01, 2018 at The Colonnade Boston Hotel, Boston, Massachusetts, United States of America.

The Synthetic Lethality Summit is the first industry-dedicated meeting that focuses on the research and development of synthetic lethal drugs, providing safe and effective treatments for a range of cancers and other diseases.

Across 3 content-packed days, the field’s thought leaders from AstraZeneca, Tesaro, Artios, Metabomed, Sierra Oncology and many more will be sharing their insight and lessons learned, collectively enabling the community to:
• Achieve Efficacy across Contexts: Define the key steps required to identify and therapeutically exploit robust synthetic lethal interactions that are conserved across a variety of defined contexts
• Optimize Patient Stratification: Streamline clinical trials by improving the recruitment and stratification of patients, increasing efficiency
• Apply Lessons Learned from PARP Inhibitors: Analyze key aspects of the development of PARP inhibitors through case studies, and determine how we can use these insights to advance R&D of new synthetic lethal drugs
• Exploit Key Targets of Mechanisms of Resistance: Assess the most effective methods for identifying and utilizing mechanisms of resistance to optimize cancer treatment
• Harness Bioinformatics and Computational Approaches: Exploring the latest advances in identifying clinically relevant synthetic lethal interactions from genome widescreens

Prices:
Conference 2 Workshops (Industry): USD 4097,
Conference 1 Workshop (Industry): USD 3398,
Conference Only (Industry): USD 2799,
Workshop Only (Industry): USD 699,
Conference 2 Workshops (Academic): USD 2868,
Conference 1 Workshop (Academic): USD 2379,
Conference Only (Academic): USD 1959,
Workshop Only (Academic): USD 699.

Speakers :
Graeme Smith - Chief Scientific Officer - Artios Pharma Ltd., J. Carl Barrett - Vice President of Translational science in Oncology - AstraZeneca, Aviad Tsherniak - Associate Director of Cancer Data Science - Broad Institute of MIT and Harvard, Alexandra Grassian - Senior Scientist - Epizyme, Cyril Benes - Director for the Center for Molecular Therapeutics - Mass General Center for Cancer Research, Simone Botti - CEO - Metabomed Ltd., René Bernards - Professor of molecular carcinogenesis - Netherlands Cancer Institute, Bill Forrester - Principal Investigator - Novartis, Dr. Mark Kowalski - Chief Medical Officer - Sierra Oncology, Jeffrey H. Hanke - Executive Vice President of Research and Development and Chief Scientific Officer - TESARO, Kevin Coleman - Executive Director Translational Research and Development Experimental Biology -, TESARO, Angelique Whitehurst - Associate Professor - UT Southwestern Medical Center, Lars Zender - Professor and Chairman of the Department of Internal Medicine VIII and Scientific Director of the Comprehensive Cancer Center - Tübingen-Stuttgart, Eytan Ruppin - Professor of Computer Science and Director of the Center of Bioinformatics and, Computational Biology (CBCB) - University of Maryland, Stephane Angers - Professor for the Faculty of Pharmacy and Dept of Biochemistry - University of Toronto, Daniel Durocher - Senior Investigator -Lunenfeld-Tanenbaum Research Institute Mount Sinai Hospital.

Additional details will be posted as soon as they are available.